Literature DB >> 18971578

The quest for the optimal assessment of global cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime?

Benoit J Arsenault1, Philippe Pibarot, Jean-Pierre Després.   

Abstract

Global risk calculators such as the Framingham risk score generally take into account traditional risk factors such as age, sex, blood pressure, smoking status, total cholesterol and high-density lipoprotein cholesterol levels, and the presence of diabetes which are recommended to be used in clinical practice to estimate patients' cardiovascular disease (CVD) risk. Over the last decades, the prevalence of obesity has dramatically increased all over the world. The deleterious form of obesity, visceral obesity, is the most prevalent form of the so-called metabolic syndrome, a constellation of risk factors associated with perturbations of the lipoprotein-lipid profile and of the plasma glucose-insulin homeostasis also likely to be associated with increased blood pressure and a proinflammatory and prothrombotic state. To this date, metabolic syndrome is still in need of a place in global CVD risk prediction. As the metabolic syndrome is not likely to replace currently used global risk scoring algorithms, both traditional risk factors and emerging metabolic markers associated with the metabolic syndrome should be incorporated in future risk scoring systems to be developed in order to adapt CVD risk prediction tools to the epidemic of obesity which has direct consequences on the daily life of health professionals. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971578     DOI: 10.1159/000165919

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  8 in total

Review 1.  Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk.

Authors:  Patrick Mathieu; Marie-Chloé Boulanger; Jean-Pierre Després
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

2.  Association of serum immunoglobulin G (IgG) levels against two periodontal pathogens and prothrombotic state: a clinical pilot study.

Authors:  Sergio Bizzarro; Elena A Nicu; Ubele van der Velden; Marja L Laine; Bruno G Loos
Journal:  Thromb J       Date:  2010-11-04

Review 3.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2013-11       Impact factor: 3.275

4.  Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study.

Authors:  Hanh-Hung Dao; Quan-Trung Do; Junichi Sakamoto
Journal:  Arthritis Res Ther       Date:  2010-12-23       Impact factor: 5.156

5.  Body fat indicators for cardiometabolic risk screening among shift workers.

Authors:  Amanda Popolino Diniz; Márcia Elivane Alves; Virgínia Capistrano Fajardo; Silvia Nascimento de Freitas; Guilherme Augusto Sousa Batista; Bruno Francia Maia Athadeu; George Luiz Lins Machado-Coelho; Fernando Luiz Pereira de Oliveira; Fausto Aloísio Pedrosa Pimenta; Raimundo Marques do Nascimento Neto
Journal:  Rev Bras Med Trab       Date:  2020-12-11

6.  Far from easy and accurate - detection of metabolic syndrome by general practitioners.

Authors:  Eeva-Eerika Helminen; Pekka Mäntyselkä; Irma Nykänen; Esko Kumpusalo
Journal:  BMC Fam Pract       Date:  2009-11-30       Impact factor: 2.497

7.  Lifestyle and dietary factors associated with the evolution of cardiometabolic risk over four years in West-African adults: the Benin study.

Authors:  Charles Sossa; Hélène Delisle; Victoire Agueh; Roger Sodjinou; Gervais Ntandou; Michel Makoutodé
Journal:  J Obes       Date:  2013-03-12

8.  Enzamin ameliorates adipose tissue inflammation with impaired adipocytokine expression and insulin resistance in db/db mice.

Authors:  Yukinori Tamura; Masato Yano; Naoyuki Kawao; Katsumi Okumoto; Shigeru Ueshima; Hiroshi Kaji; Osamu Matsuo
Journal:  J Nutr Sci       Date:  2013-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.